Tags

Type your tag names separated by a space and hit enter

Prognosis and cure of long-term cancer survivors: A population-based estimation.
Cancer Med 2019; 8(9):4497-4507CM

Abstract

BACKGROUND

Increasing evidence of cure for some neoplasms has emerged in recent years. The study aimed to estimate population-based indicators of cancer cure.

METHODS

Information on more than half a million cancer patients aged 15-74 years collected by population-based Italian cancer registries and mixture cure models were used to estimate the life expectancy of fatal tumors (LEFT), proportions of patients with similar death rates of the general population (cure fraction), and time to reach 5-year conditional relative survival (CRS) >90% or 95% (time to cure).

RESULTS

Between 1990 and 2000, the median LEFT increased >1 year for breast (from 8.1 to 9.4 years) and prostate cancers (from 5.2 to 7.4 years). Median LEFT in 1990 was >5 years for testicular cancers (5.8) and Hodgkin lymphoma (6.3) below 45 years of age. In both sexes, it was ≤0.5 years for pancreatic cancers and NHL in 1990 and in 2000. The cure fraction showed a 10% increase between 1990 and 2000. It was 95% for thyroid cancer in women, 94% for testis, 75% for prostate, 67% for breast cancers, and <20% for liver, lung, and pancreatic cancers. Time to 5-year CRS >95% was <10 years for testis, thyroid, colon cancers, and melanoma. For breast and prostate cancers, the 5-year CRS >90% was reached in <10 years but a small excess remained for >15 years.

CONCLUSIONS

The study findings confirmed that several cancer types are curable. Became aware of the possibility of cancer cure has relevant clinical and social impacts.

Authors+Show Affiliations

Cancer Epidemiology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.Cancer Epidemiology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.Veneto Tumour Registry, Azienda Zero, Padua, Italy.Cancer Epidemiology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.National Center for Prevention and Health Promotion, Italian National Institute of Health (ISS), Rome, Italy.Evaluative Epidemiology Unit, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.Cancer Epidemiology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.National Center for Prevention and Health Promotion, Italian National Institute of Health (ISS), Rome, Italy.Institute for Research on Population and Social Policies, National Research Council, Rome, Italy.Romagna Cancer Registry, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS and Azienda Usl della Romagna, Meldola (Forlì), Italy.Veneto Tumour Registry, Azienda Zero, Padua, Italy. Department of Medicine (DIMED), University of Padua, Padua, Italy.Lombardy Cancer Registry-Varese Province, Cancer Registry Unit, Department of Research, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.Liguria Cancer Registry, Clinical Epidemiology, IRCCS Policlinico San Martino, Genova, Italy.Modena Cancer Registry, Public Health Department, AUSL Modena, Modena, Italy.Parma Cancer Registry, Oncology Unit, Azienda Ospedaliera Universitaria di Parma, Parma, Italy.Romagna Cancer Registry - Section of Ferrara. Local Health Unit, University of Ferrara, Ferrara, Italy.North Sardinia Cancer Registry, Azienda Regionale per la Tutela della Salute, Sassari, Italy.Cancer Registry, ASP Ragusa, Victoria, Italy.Romagna Cancer Registry, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS and Azienda Usl della Romagna, Meldola (Forlì), Italy.Public Health Section, Department of Experimental Medicine, University of Perugia, Perugia, Italy.Registro Tumori Integrato Catania-Messina-Siracusa-Enna, Catania, Italy.South-Tyrol Tumor Registry, Bolzano, Italy.Cancer Registry of ASL Napoli 3 Sud, Napoli, Italy.Registro Tumori Piemonte, Provincia di Biella CPO, Biella, Italy.Cancer Registry of the Province of Siracusa, Local Health Unit of Siracusa, Siracusa, Italy.Sondrio Cancer Registry, Epidemiology unit, ATS della Montagna, Sondrio, Italy.Nuoro Cancer Registry, ASSL Nuoro/ATS Sardegna, Nuoro, Italy.Tuscany Cancer Registry, Clinical and Descriptive Epidemiology Unit, Cancer Prevention and Research Institute (ISPO), Florence, Italy. AIRTUM Database, Florence, Italy.Department of Oncology and Molecular Medicine, Italian National Institute of Health (ISS), Rome, Italy.No affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31207165

Citation

Dal Maso, Luigino, et al. "Prognosis and Cure of Long-term Cancer Survivors: a Population-based Estimation." Cancer Medicine, vol. 8, no. 9, 2019, pp. 4497-4507.
Dal Maso L, Panato C, Guzzinati S, et al. Prognosis and cure of long-term cancer survivors: A population-based estimation. Cancer Med. 2019;8(9):4497-4507.
Dal Maso, L., Panato, C., Guzzinati, S., Serraino, D., Francisci, S., Botta, L., ... De Angelis, R. (2019). Prognosis and cure of long-term cancer survivors: A population-based estimation. Cancer Medicine, 8(9), pp. 4497-4507. doi:10.1002/cam4.2276.
Dal Maso L, et al. Prognosis and Cure of Long-term Cancer Survivors: a Population-based Estimation. Cancer Med. 2019;8(9):4497-4507. PubMed PMID: 31207165.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prognosis and cure of long-term cancer survivors: A population-based estimation. AU - Dal Maso,Luigino, AU - Panato,Chiara, AU - Guzzinati,Stefano, AU - Serraino,Diego, AU - Francisci,Silvia, AU - Botta,Laura, AU - Capocaccia,Riccardo, AU - Tavilla,Andrea, AU - Gigli,Anna, AU - Crocetti,Emanuele, AU - Rugge,Massimo, AU - Tagliabue,Giovanna, AU - Filiberti,Rosa Angela, AU - Carrozzi,Giuliano, AU - Michiara,Maria, AU - Ferretti,Stefano, AU - Cesaraccio,Rosaria, AU - Tumino,Rosario, AU - Falcini,Fabio, AU - Stracci,Fabrizio, AU - Torrisi,Antonietta, AU - Mazzoleni,Guido, AU - Fusco,Mario, AU - Rosso,Stefano, AU - Tisano,Francesco, AU - Fanetti,Anna Clara, AU - Sini,Giovanna Maria, AU - Buzzoni,Carlotta, AU - De Angelis,Roberta, AU - ,, Y1 - 2019/06/17/ PY - 2019/04/11/received PY - 2019/05/06/accepted PY - 2019/6/18/pubmed PY - 2019/6/18/medline PY - 2019/6/18/entrez KW - Italy KW - cancer cure KW - population-based cancer registries KW - prevalence KW - survival SP - 4497 EP - 4507 JF - Cancer medicine JO - Cancer Med VL - 8 IS - 9 N2 - BACKGROUND: Increasing evidence of cure for some neoplasms has emerged in recent years. The study aimed to estimate population-based indicators of cancer cure. METHODS: Information on more than half a million cancer patients aged 15-74 years collected by population-based Italian cancer registries and mixture cure models were used to estimate the life expectancy of fatal tumors (LEFT), proportions of patients with similar death rates of the general population (cure fraction), and time to reach 5-year conditional relative survival (CRS) >90% or 95% (time to cure). RESULTS: Between 1990 and 2000, the median LEFT increased >1 year for breast (from 8.1 to 9.4 years) and prostate cancers (from 5.2 to 7.4 years). Median LEFT in 1990 was >5 years for testicular cancers (5.8) and Hodgkin lymphoma (6.3) below 45 years of age. In both sexes, it was ≤0.5 years for pancreatic cancers and NHL in 1990 and in 2000. The cure fraction showed a 10% increase between 1990 and 2000. It was 95% for thyroid cancer in women, 94% for testis, 75% for prostate, 67% for breast cancers, and <20% for liver, lung, and pancreatic cancers. Time to 5-year CRS >95% was <10 years for testis, thyroid, colon cancers, and melanoma. For breast and prostate cancers, the 5-year CRS >90% was reached in <10 years but a small excess remained for >15 years. CONCLUSIONS: The study findings confirmed that several cancer types are curable. Became aware of the possibility of cancer cure has relevant clinical and social impacts. SN - 2045-7634 UR - https://www.unboundmedicine.com/medline/citation/31207165/Prognosis_and_cure of_long-term_cancer_survivors:_A_population-based_estimation L2 - https://doi.org/10.1002/cam4.2276 DB - PRIME DP - Unbound Medicine ER -